Image source: Boston Scientific Corporation.
What: After reporting first-quarter financial results that were better than industry watchers were anticipating, shares of Boston Scientific Corporation (BSX 5.68%) soared 11.2 % today.
So what: The medical technology maker best known for its heart-related product line reported earlier today that sales climbed 11.1% to $1.96 billion in the first quarter. Those sales were comprised of $790 million in revenue from cardiovascular products, $492 million in sales from its rhythm management products, and $682 million in sales from its MedSurg business segment.
Boston Scientific's management also said its net income jumped 32.2% on a non-GAAP basis to $378 million, resulting in non-GAAP EPS of $0.28 per share, up from $0.21 a year ago.
The company's sales outpaced industry analysts forecast by $50 million, while the bottom line came in $0.04 ahead of estimates. Importantly, the ability for the company to deliver organic (non-M&A related) revenue growth of 8% in the quarter suggests its products are gaining market share.
Now what: Thanks to the better-than-hoped first-quarter performance, management is upping its full-year sales forecast to a range of $8.075 to $8.225 billion from prior guidance of between $7.9 to $8.1 billion. It's also increasing its non-GAAP EPS estimate for the year to at least $1.06 from prior expectations for at least $1.03.
Overall, if Boston Scientific can deliver on that promise, it would represent 8% to 10% year-over-year growth versus 2015, or 9% to 11% on an operational basis. Given the potential for rising demand tied to an older and increasingly insured population and the potential for profit upside, I think this company may be worth buying.
